✦ LIBER ✦

Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers

✍ Scribed by Danielle Vicus; Barry Rosen; Jan Lubinski; Susan Domchek; Noah D. Kauff; Henry T. Lynch; Claudine Isaacs; Nadine Tung; Ping Sun; Steven A. Narod

Book ID: 113962121
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 131 KB
Volume: 115
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2009.06.012

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ovarian cancer susceptibility alleles an

Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

✍ Susan J. Ramus; Antonis C. Antoniou; Karoline B. Kuchenbaecker; Penny Soucy; Jon 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 361 KB 👁 1 views

Germline mutations in BRCA1 and BRCA2 are associated with increased risks of breast and ovarian cancer. A genome-wide association study (GWAS) identified six alleles associated with risk of ovarian cancer for women in the general population. We evaluated four of these loci as potential modifiers of

Tamoxifen and Risk of Contralateral Brea

Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

✍ Phillips, K.-A.; Milne, R. L.; Rookus, M. A.; Daly, M. B.; Antoniou, A. C.; Peoc 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 142 KB

Anthropometric Measures and Risk of Ovar

Anthropometric Measures and Risk of Ovarian Cancer Among BRCA1 and BRCA2 Mutation Carriers

✍ Jacob McGee; Joanne Kotsopoulos; Jan Lubinski; Henry T. Lynch; Barry Rosen; Nadi 📂 Article 📅 2012 🏛 Nature Publishing Group 🌐 English ⚖ 134 KB

The risk of primary and contralateral br

The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1 / BRCA2 mutation carriers

✍ Vencken, Peggy M. L. H.; Kriege, Mieke; Hooning, Maartje; Menke-Pluymers, Marian 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 204 KB

Hormone replacement therapy and the risk

Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

✍ Joanne Kotsopoulos; Jan Lubinski; Susan L. Neuhausen; Henry T. Lynch; Barry Rose 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 100 KB

Duration of tamoxifen use and the risk o

Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

✍ Gronwald, Jacek; Robidoux, Andre; Kim-Sing, Charmaine; Tung, Nadine; Lynch, Henr 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 192 KB